Literature DB >> 1787131

Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange.

A W Roberts1, E A Gillett, S J Fleming.   

Abstract

A retrospective analysis was made of 14 consecutive adults with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) who were treated with plasma exchange (PE). In six patients the disease was primary, whilst in eight HUS/TTP was considered secondary to an associated condition. Thirteen patients had renal involvement, six had central nervous system symptoms or signs, three had fever, and one had myocardial damage. Twelve patients (86%) recovered. Four of these relapsed, but responded to further treatment. Two patients failed to respond and died. Hematological response occurred rapidly in survivors: thrombocytopenia resolved after a median of four exchanges, and hemolysis after a median of six. Four patients had a complete recovery, seven had residual mild end organ damage, and one had severe renal impairment. PE was an effective treatment for both primary and secondary HUS/TTP. The platelet count proved to be the earliest indicator of clinical outcome. Continuing follow-up of survivors is required because of the risk of relapse and the high incidence of end organ damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1787131     DOI: 10.1002/jca.2920060305

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  5 in total

Review 1.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

2.  Diagnosis and management of atypical hemolytic uremic syndrome in children: single centre experience.

Authors:  Rashmi D Patel; Aruna V Vanikar; Manoj R Gumber; Kamal V Kanodia; Kamlesh S Suthar; Himanshu V Patel; Hargovind L Trivedi
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-08       Impact factor: 0.900

3.  Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.

Authors:  A Donohue-Rolfe; I Kondova; J Mukherjee; K Chios; D Hutto; S Tzipori
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

4.  Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Cassiana E Bittencourt; Jennifer P Ha; Robert W Maitta
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

5.  Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States.

Authors:  Ayoade Adeyemi; Francesca Razakariasa; Alexandra Chiorean; Rui de Passos Sousa
Journal:  Res Pract Thromb Haemost       Date:  2022-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.